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Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human
hepatocellular carcinoma
Aims: To correlate microvascular density and erythro-
poietin (Epo) ⁄ Epo-receptor (EpoR) expression in endo-
thelial and tumour cells with histopathological type in
hepatocellular carcinoma (HCC).
Methods and results: Specimens of primary HCC
obtained from 50 patients who had undergone curative
hepatectomy were investigated immunohistochemic-
ally by using anti-CD31, anti-Epo and anti-EpoR
antibodies. Poorly differentiated HCC had a higher
degree of vascularization than other stages and
Epo ⁄ EpoR expression in both tumour and endothelial
cells increased in parallel with grade of malignancy and
was highly correlated with the extent of angiogenesis.
Conclusions: Epo ⁄ EpoR levels correlate with angio-
genesis and progression of patients with HCC and
these ﬁndings suggest the presence of a loop in the
Epo ⁄ EpoR system, i.e. Epo is secreted by hepatic
tumour cells and it affects vascular endothelial cells
via its receptors and promotes angiogenesis in a
paracrine manner. It is thus suggested that Epo is an
important factor in hepatic tumour angiogenesis.
Understanding the mechanisms of HCC angiogenesis
provides a basis for a rational approach to the
development of antiangiogenic therapy in patients
with hepatic cancer.
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Introduction
Erythropoietin (Epo) is a low-molecular-weight glyco-
protein hormone stimulator of erythropoiesis produced
in the fetal liver and subsequently in the adult kidney.
1
Epo exerts its action through its speciﬁc receptor
(EpoR), a member of the cytokine receptor superfamily,
which is mainly expressed on erythroid colony-forming
units.
2
Epo is a pleiotropic cytokine that exerts diverse
biological effects in many non-haematopoietic tissues.
There is increasing evidence suggesting a wider bio-
logical role for Epo ⁄ EpoR unrelated to erythropoiesis.
Angiogenesis, the process by which new blood vessels
arise from pre-existing ones, has been shown to be
one of the extrahaematopoietic functions of Epo.
3
The precise role of Epo in angiogenesis has not been
clariﬁed, although many critical functions of Epo have
been reported. Endothelial cells from some sources
express EpoR.
4 Moreover, Epo induces endothelial cell
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4–6 and has been shown to
stimulate angiogenesis in rat aortic rings in vitro.
7 We
have demonstrated that recombinant human Epo
(rhEpo) induces a proangiogenic phenotype in human
endothelial cells.
8 This phenotype includes both early
(i.e. increase in cell proliferation and matrix metallo-
proteinase-2 production) and late (differentiation into
vascular tubes) angiogenic events. Accordingly, endo-
thelial cells express EpoR that bind to Jak2 and induce
its transient activation after rhEpo exposure. In the
chick embryo chorioallantoic membrane (CAM) assay,
the angiogenic activity of rhEpo is quantitatively and
qualitatively similar to that exerted by ﬁbroblast
growth factor-2 (FGF-2) and CAM endothelial cells
express EpoR that colocalizes with factor VIII-related
antigen positivity. Jaquet et al.
9 found the angiogenic
potential of Epo to be similar to that of vascular
endothelial growth factor (VEGF) when stimulating
human adult myocardial endothelial cells.
The potential role of Epo in angiogenesis may be
considered as a subsidiary of its possible function in
improving overall tissue oxygenation and of its anti-
apoptotic role. The expression of EpoR in tumour
vascular endothelium suggests that Epo may affect the
tumour microenvironment, perhaps by stimulating
tumour angiogenesis.
3
Experimental and clinical data indicate that tumour
progression in human hepatocellular carcinoma (HCC)
is associated with angiogenesis and that an increase in
microvascular density is associated with a poor prog-
nosis.
10 It is becoming increasingly evident that agents
which interfere with blood vessel formation also block
tumour progression. Accordingly, antiangiogenic tu-
mour therapy has attracted much interest in preclinical
and clinical assessments of HCC.
11
In this study, we investigated immunohistochemical
expression of Epo ⁄ EpoR in HCC and correlated this
with CD31 expression in vascular endothelial cells with
the aim of establishing a potential role for Epo in
angiogenesis in HCC.
Materials and methods
patient population and tumours
Fifty patients (26 males and 24 females, mean age
61 ± 5 years, range 22–75) with a singular nodule of
HCC who had undergone curative hepatectomy from
January 1996 to December 2002 at the Hepato-Biliary-
Pancreatic Surgery Division, University of Bari Medical
School, were included in the study. Patients who had
had a previous hepatectomy or hepatic arterial chemo-
embolization were excluded. All patients had liver
cirrhosis, they were not alcoholic and tested negative
for hepatitis B surface antigen (HBsAg) and for
antibodies to hepatitis C (anti-HCV). HCC tissues and
surrounding cirrhotic liver tissues were examined.
Liver biopsy samples from 10 patients with minimal
reactive changes (normal liver) or with histological
changes of non-immune-mediated cholestasis (mild
portal inﬂammation and ⁄ or ductular hyperplasia) were
also studied. Biopsies were obtained during abdominal
surgery for uncomplicated cholelithiasis and all
these patients were negative for HBsAg, anti-HCV
and autoantibodies. Tumours were graded as well dif-
ferentiated (tumour size maximum diameter ¼ 30.0 ±
15.4 mm), moderately differentiated (tumour size
maximum diameter ¼ 51.5 ± 24.6 mm) or poorly dif-
ferentiated (tumour size maximum diameter ¼ 82.4 ±
42.3 mm). HCC develops and progresses from a small-
sized, well-differentiated histotype with no developed
blood vessels to a larger and moderately differentiated
or poorly differentiated one with characteristic hyper-
vascularity during the differentiation process.
12 Tissue
samples were ﬁxed in 10% buffered formalin and
embedded in parafﬁn according to standard procedures.
Sections (4 lm thick) were cut and mounted on glass
slides.
immunohistochemistry
A murine monoclonal antibody (MAb) against the
endothelial cell marker CD31, a more sensitive marker
for endothelial cells than factor VIII antigen
13 (MAb
1A10; DakoCytomation, Glostrup, Denmark) and two
rabbit polyclonal antibodies against Epo and EpoR
(N19 and C20; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were used. The anti-Epo and the anti-
EpoR antibodies are two afﬁnity-puriﬁed rabbit poly-
clonal antibodies raised against a peptide mapping at
the N-terminus of Epo and, respectively, against amino
acids 21–214 mapping near the N-terminus of EpoR
of human origin. Brieﬂy, sections were collected on
3-amino-propyl-triethoxysilane-coated slides, deparafﬁ-
nized by the xylene–ethanol sequence, rehydrated in a
graded ethanol scale and in Tris-buffered saline (TBS,
pH 7.6) and incubated overnight at 4 C with the MAb
1A10 (1 : 25 in TBS) and the polyclonal antibodies
N19 and C20 (1 : 200 in TBS), after prior antigen
retrieval by heating the sections in a pressure cooker in
1 mmol ⁄ l ethylenediamine tetraacetic acid buffer,
pH 8.0 for 1.5 h. As for CD31 immunostaining, the
sections were incubated with biotinylated IgG and
then with peroxidase-conjugated streptavidin (LSAB2;
DakoCytomation). The colour was developed by
diaminobenzidine. The immunodetection of Epo and
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alkaline phosphatase (DakoCytomation) and fast red as
chromogen, followed by haematoxylin counterstaining.
Negative controls included an unrelated monoclonal
IgG1 produced by the P3X63 ⁄ Ag8 mouse secretory
myeloma replacing the antibody, for the MAb against
CD31
14 and preincubation with a 10-fold excess of
speciﬁc blocking peptide (Santa Cruz) for the polyclonal
antibodies against Epo and EpoR.
microvessel density, epo and epor expression
counting
These were simultaneously assessed without knowledge
of the ﬁnal pathological diagnosis by two investigators
with a double-headed light microscope (Axioplan II;
Zeiss, Oberkochen, Germany). Four to six 200· ﬁelds
covering almost the whole of each of three sections per
sample were examined with a 144-intersection point
square reticulum (0.78 mm
2) inserted in the eyepiece.
Care was taken to select microvessels, i.e. capillaries
and small venules, from all the CD31-stained vessels.
They were identiﬁed as transversely sectioned tubes
with a single layer of endothelial cells, with or without
a thin basement membrane. Each assessment was
agreed upon in turn. Microvessels were counted with a
planimetric point-count method with slight modiﬁca-
tions to restrict counting to transversely cut microves-
sels occupying the reticulum intersection points.
15 As
the microvessel diameter was smaller than the distance
between adjacent points, only one transversely sec-
tioned microvessel could occupy a given point. Micro-
vessels transversely sectioned outside the points and
those longitudinally or tangentially sectioned were
omitted. Therefore, it was sufﬁciently certain that a
given microvessel was counted only once, even in the
presence of several of its section planes. As almost the
entire section was analysed per sample and as trans-
versely sectioned microvessels hit the intersection
points randomly, the method allowed objective counts.
Tumour and endothelial cells stained with anti-CD31,
anti-Epo and anti-EpoR antibodies were counted on
four to six ﬁelds covering the whole of each of three
sections adjacent to those stained for microvessels and
means ±1 SD and medians were determined for each
section, sample and group of samples. The relationship
between microvessel density, Epo and EpoR expression
and histopathological type was examined by v
2 test
or logistic regression analysis. A cut-off value of 10
marked cells was assigned to microvessel density and to
EpoR expression in endothelial cells and of 30 marked
cells to EpoR expression in tumour cells. Statistical
signiﬁcance was deﬁned as P < 0.05.
Results
In normal liver, staining with anti-CD31 revealed only
focal reactivity of a few sinusoids (Figure 1A). In
cirrhotic liver tissue there was a moderate increase in
the number of sinusoids stained by anti-CD31 com-
pared with the normal liver (Figure 1B). Moreover,
endothelial immunostaining of liver sections with an
anti-CD31 antibody showed the formation of tubular-
like structures in inﬂamed portal tracts and septa.
Expression of CD31 binding sites was detected in the
sinusoidal endothelial cells of cancerous tissues. This
expression was stronger in poorly differentiated HCC
(Figure 1C) than in well-differentiated HCC. Compar-
ison with adjacent non-cancerous areas showed that
this expression was stronger in cancerous areas than in
adjacent non-cancerous areas.
EpoR was diffusely and strongly expressed on sinu-
soidal endothelial cells within neoplastic nodules
A
B
C
Figure 1. Immunohistochemical reactivity for CD31 in human
hepatocellular carcinoma (HCC). Note in (A) focal reactivity of a few
sinusoids in normal liver; in (B) a moderate increase in cirrhotic liver
and in (C) strong immunoreactivity in a poorly differentiated HCC.
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reactivity was also noted in a few HCC cells
(Figure 2B). A less intense and focal positivity was
detected on the sinusoids of the adjacent cirrhotic
areas, whereas epithelial cirrhotic cells were negative
(Figure 2C). In most cases Epo showed a weak and
focal cytoplasmic granular pattern in HCC cells, more
prominent in poorly differentiated cases (Figure 2D)
than in better differentiated ones; cirrhotic nodules
were unstained (Figure 2E).
A
B
D
E
C
Figure 2. Immunohistochemical reactivity for erythropoietin (Epo) and
erythropoietin receptor (EpoR) in human hepatocellular carcinoma
(HCC). Note in (A) strong immunoreactivity for EpoR in sinusoidal
endothelial cells in a poorly differentiated HCC; in (B) membrane-
linear ⁄ cytoplasmic staining for EpoR in tumour cells of a poorly
differentiated HCC; in (C) absence of staining for EpoR in cirrhotic cells; in
(D) weak and cytoplasmic granular staining for Epo in tumour cells of a
poorly differentiated HCC; in (E) absence of staining for Epo in cirrhotic
cells.
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Epo and EpoR counts and histological tumour grade.
The comparison of microvessel counts between histo-
logical groups revealed statistically signiﬁcant differ-
ences. When differences were sought between groups,
signiﬁcantly higher counts were found in poorly
differentiated HCC compared with other stages
(P<0.001). Regarding differences in microvessel,
Epo and EpoR expression in both endothelial and
tumour cells, the within-group comparison showed
that both counts were always signiﬁcantly correlated.
There was a trend for these three parameters to
increase with histological grade. The counts of pati-
ents with poorly differentiated HCC were signiﬁcantly
higher (P<0.001) than those of patients with mode-
rately and well-differentiated HCC, respectively.
Discussion
The results of this study have shown that ‘poorly
differentiated’ HCC has a higher degree of vasculariza-
tion than ‘moderately’ and ‘well-differentiated’ HCC,
respectively, and that Epo expression in tumour cells
and EpoR expression in both tumour and endothelial
cells increases in parallel with the grade of malignancy
and is highly correlated with the extent of angiogen-
esis. Tumour angiogenesis does not depend on a single
molecule, since many angiogenic inducers and inhib-
itors are simultaneously expressed. Secretion by HCC
cells, inﬁltrating inﬂammatory cells and hepatic stellate
cells of several angiogenic cytokines, such as VEGF,
FGF-2, angiogenin, angiopoietins and Epo promotes the
sprouting of new vessels from pre-existing ones.
The presence of an autocrine-paracrine Epo–EpoR
system in tumours and the possible effects of Epo on the
tumour microenvironment and angiogenesis are con-
sistent with a complex biology for Epo–EpoR signalling
in cancer.
Kayser and Gabius
16 ﬁrst suggested that human
tumours may express EpoR. In their study 81% of
human lung carcinoma tissues possessed Epo-binding
sites, detected by the use of biotinylated rhEpo. EpoR
transcripts and EpoR protein were subsequently
demonstrated in human renal carcinoma,
17 tumours
of the cervix and other organs of the female reproduc-
tive tract
18–20 and in various specimens of common
paediatric tumours such as neuroblastomas, brain
tumours, hepatoblastomas and Wilms’ tumours.
21 By
immunohistochemistry, EpoR has been shown to be
expressed in breast carcinoma
22–24 and in vestibular
schwannoma.
25 Yasuda et al.
26 studied the expression
of Epo in several malignant human cell lines and found
that they express Epo and EpoR regardless of their
origins, types, genetic characteristics and biological
properties, that they secrete a very small amount of Epo
individually and that most of them respond to hypoxic
stimuli by enhanced secretion of Epo.
There is evidence that HCC produces marked erythro-
cytosis and is associated with increased levels of serum
Epo or the production of Epo-like activity in cell cul-
tures.
27,28 Because HCC is a hypervascular tumour and
the liver and kidney are major Epo production sites, it is
suggested that Epo signalling may contribute to
the development and progression of malignant hepatic
tumours.
Sugimachi et al.
29 investigated Epo expression in a
human HCC line and demonstrated that Epo was up-
regulated in hypoxic conditions. Nakamatsu et al.
30
investigated the expression of Epo and EpoR in murine
chemically induced hepatic tumours. They showed
that Epo was not detectable in the normal or cirrhotic
liver tissues without tumours, while immunoreactive
EpoR was detectable in the endothelium of intervening
vessels of all hepatic tumours. No immunoreactive EpoR
was discernible in the wall of the hepatic vasculature in
thecirrhotictissues adjacenttothetumours.Thereason
forthisselectiveexpressionofEpoRinthetumourvessels
is unclear. The immature nature of tumour vessels
compared with mature hepatic vessels may be related to
the selective expression of EpoR.
These ﬁndings suggest the presence of a loop in the
Epo–EpoR system, i.e. Epo is secreted by hepatic tumour
cells and it affects vascular endothelial cells via its
receptors and promotes angiogenesis in a paracrine
manner. Thus, it is suggested that Epo is an important
factor in hepatic tumour angiogenesis.
Table 1. Correlation
between histological grade,
microvessel density, ery-
thropoietin (Epo) and ery-
thropoietin receptor (EpoR)
expression in hepatocellular
carcinoma
Histological
grade Cases
Microvessel
density
Epo expression,
tumour cells
EpoR expression
Endothelial cells Tumour cells
Poorly differentiated 14 32 ± 6* 13 ± 4* 27 ± 5* 15 ± 6*
Moderately differentiated 12 20 ± 4* 9 ± 3* 17 ± 4* 10 ± 3*
Well differentiated 24 15 ± 5 5 ± 2 12 ± 4 7 ± 2
*P<0.001 compared with well differentiated.
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provides the basis for a rational approach to the
development of antiangiogenic therapy in patients with
HCC. Inhibition of Epo signalling, by the injection of an
anti-EpomonoclonalantibodyorasolubleformofEpoR,
resultsindelayoftumourgrowthinovariananduterine
cancers.
18 In nude mice, Yasuda et al.
26 blocked the Epo
signallinginxenograftsoftworepresentativecelllinesby
intraperitoneal injections of EpoR antagonist and found
inhibition of angiogenesis and survival of tumour cells
leading to destruction of tumour masses.
These results may have implications for the treat-
ment of HCC by inhibition of the Epo–EpoR system.
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